Janus Henderson Group PLC Has $72.49 Million Holdings in CVS Health Corp (CVS)

Janus Henderson Group PLC boosted its holdings in shares of CVS Health Corp (NYSE:CVS) by 21.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 891,437 shares of the pharmacy operator’s stock after purchasing an additional 159,671 shares during the quarter. Janus Henderson Group PLC’s holdings in CVS Health were worth $72,488,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Pathstone Family Office LLC increased its holdings in CVS Health by 341.0% during the 2nd quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock worth $2,353,000 after purchasing an additional 982 shares during the last quarter. Fieldpoint Private Securities LLC grew its position in shares of CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 1,000 shares in the last quarter. Arcadia Investment Management Corp MI grew its position in shares of CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after acquiring an additional 726 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new position in shares of CVS Health in the 2nd quarter worth approximately $119,000. Finally, Captrust Financial Advisors acquired a new position in shares of CVS Health in the 2nd quarter worth approximately $155,000. Institutional investors own 81.69% of the company’s stock.

CVS Health Corp (CVS) opened at $70.55 on Friday. CVS Health Corp has a 12-month low of $66.45 and a 12-month high of $84.00. The stock has a market capitalization of $75,315.95, a P/E ratio of 13.02, a P/E/G ratio of 1.24 and a beta of 0.93. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The business had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. During the same quarter in the previous year, the firm posted $1.71 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. equities analysts forecast that CVS Health Corp will post 5.88 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Investors of record on Wednesday, January 24th were given a dividend of $0.50 per share. The ex-dividend date was Tuesday, January 23rd. This represents a $2.00 dividend on an annualized basis and a yield of 2.83%. CVS Health’s dividend payout ratio is currently 41.32%.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.61% of the company’s stock.

Several research analysts have recently commented on CVS shares. Needham & Company LLC reiterated a “hold” rating on shares of CVS Health in a research report on Thursday, October 12th. SunTrust Banks set a $85.00 target price on CVS Health and gave the stock a “buy” rating in a research report on Thursday, October 12th. Jefferies Group set a $86.00 target price on CVS Health and gave the stock a “hold” rating in a research report on Wednesday, October 18th. Mizuho set a $90.00 target price on CVS Health and gave the stock a “buy” rating in a research report on Tuesday, October 24th. Finally, Robert W. Baird reiterated a “hold” rating and issued a $77.00 target price on shares of CVS Health in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $88.27.

COPYRIGHT VIOLATION WARNING: “Janus Henderson Group PLC Has $72.49 Million Holdings in CVS Health Corp (CVS)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2018/02/09/janus-henderson-group-plc-has-72-49-million-holdings-in-cvs-health-corp-cvs.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply